About this trial
Microwave ablation is a minimally invasive technique whose planning relies on manufacturer tables derived from ex vivo models that do not account for patient or tumor-specific factors. In clinical practice, the actual ablation volume often differs from the planned volume due to liver characteristics, vascular proximity, and tumor biology.
This study aims to assess the variability between ablation small axis during percutaneous microwave ablation of liver lesions. The influence of patient-related (fibrosis, steatosis, portal flow) and tumor-related factors (location, histology, prior treatment) will be evaluated. Small axis and volume will be compared with volumes measured on immediate post-procedural CT and on CT/MRI at 6-12 weeks, accounting for expected tissue shrinkage.
Eligibility criteria
Qualifiers
Adult patients
Treated with percutaneous hepatic microwave ablation under CT or ultrasound guidance
Adult treated for one or more liver lesions
Patients with available follow-up imaging
Disqualifiers
Two treatment cycles on the same lesion during the same session.
Reoperation on the same lesion.
Planned volume not available (no manufacturer data, not specified in the surgical report).
No control imaging injected between 1 and 4 months post-procedure.
Trial design
Treatments tested in this trial
- Not listed